menu
    • menu

    Company profile for Modalis Therapeutics

    NEW Drugs in Dev: 2
    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    Nanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Virtual Booth

    Contact Supplier

    Ever Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances, suspensions, etc.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Modalis Therapeutics Corporation (Tokyo Mothers 4883) is developing precision genetic medicines through epigenetic gene modulation. Modalis is advancing therapies for orphan genetic diseases using its proprietary CRISPR-GNDM technology which enables the locus specific modulation of gene expression or histone modification without the need for double- stranded DNA cleavage, gene editing or base editing. Modalis is headquartered ...
    Modalis Therapeutics Corporation (Tokyo Mothers 4883) is developing precision genetic medicines through epigenetic gene modulation. Modalis is advancing therapies for orphan genetic diseases using its proprietary CRISPR-GNDM technology which enables the locus specific modulation of gene expression or histone modification without the need for double- stranded DNA cleavage, gene editing or base editing. Modalis is headquartered in Tokyo with laboratories and R&D facilities in Cambridge.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Modalis TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Cambridge, Massachusetts
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.modalistx.com/en/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/modalistx/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    SOLVE, Modalis Team Up for CRISPR FSHD Therapy Program
    SOLVE, Modalis Team Up for CRISPR FSHD Therapy Program

    08 Jun 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250608851515/en/SOLVE-FSHD-and-Modalis-Announce-Strategic-Collaboration-to-Develop-an-Innovative-CRISPR-Based-Epigenome-Editing-Treatment-for-Facioscapulohumeral-Muscular-Dystrophy

    BUSINESSWIRE
    08 Jun 2025
    Share Share
    Modalis Chosen as Finalist in XPRIZE FSHD Competition
    Modalis Chosen as Finalist in XPRIZE FSHD Competition

    12 May 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250512307474/en/Modalis-has-been-selected-as-a-finalist-in-the-XPRIZE-Healthspan-FSHD-Bonus-Prize-Competition-and-awarded-research-funds.

    BUSINESSWIRE
    12 May 2025
    Share Share
    JCR-Modalis Move To Next Phase For Novel Gene Therapy Research
    JCR-Modalis Move To Next Phase For Novel Gene Therapy Research

    05 Jan 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250105566917/en

    BUSINESSWIRE
    05 Jan 2025
    Share Share
    Modalis Receives Orphan Drug Designation for MDL-101 in CMD
    Modalis Receives Orphan Drug Designation for MDL-101 in CMD

    25 Oct 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241024759996/en

    BUSINESSWIRE
    25 Oct 2024
    Share Share
    Modalis FDA Grants Pediatric Disease Designation To MDL-101 for DMD
    Modalis FDA Grants Pediatric Disease Designation To MDL-101 for DMD

    30 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240929247973/en

    BUSINESSWIRE
    30 Sep 2024
    Share Share
    Modalis Data On Epigenome Editing For Muscular Dystrophy
    Modalis Data On Epigenome Editing For Muscular Dystrophy

    07 May 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240506038609/en

    BUSINESSWIRE
    07 May 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search